Sign in

SMTI on Nasdaq

Sanara MedTech Inc.

Sanara MedTech Inc. is an American orthopedic company based in Fort Worth, listed on Nasdaq (SMTI).1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with ALPHA PRO TECH LTD, Lakeland Industries or ESTABLISHMENT LABS HOLDINGS INC., or pick any stock.

  • TickerSMTI on Nasdaq1
  • IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies1
  • HeadquartersFort Worth, Texas1
  • Incorporated inTX2
  • Business address1200 Summit Ave, Suite 414, Fort Worth, Tx 761022
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Verified Inductive Bone Matrix is a naturally derived, differentiated allograft matrix with robust handling properties.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

92.7%Gross margin5
7.1%Operating margin5
-36.4%Net margin5
19.0%Revenue growth, 20255
-632.5%Return on equity5
7.74×Debt to equity5
$2.2MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Soft Tissue Repair Products brought in 89% of the revenue Sanara MedTech Inc. broke down this way in fiscal 2025.

  1. Soft Tissue Repair Products$91.3M589%up 20% from 2024
  2. Bone Fusion Products$11.8M511%up 12% from 2024
Products and services by year
Products and services20242025
Soft Tissue Repair Products$76.1M$91.3M
Bone Fusion Products$10.5M$11.8M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue7¢$7.5M
  • Research and development5¢$5.1M
  • Selling, general and admin76¢$78.7M
  • Other costs5¢$5.0M
  • Interest7¢$6.8M

Out of $103.1M in revenue.5 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending68¢$4.6M
  • Kept or used elsewhere32¢$2.2M

Out of $6.8M of cash from operations.5

Financial statements

Revenue6789105$103.1M in 2025+776% since 2019
0$50.0M$100.0M$150.0M2019: $11.8M$11.8M20192020: $15.6M$15.6M2020+32%2021: $24.1M$24.1M2021+55%2022: $45.8M$45.8M2022+90%2023: $65.0M$65.0M2023+42%2024: $86.7M$86.7M2024+33%2025: $103.1M$103.1M2025+19%
Gross profit6789105$95.6M in 2025+805% since 2019
0$25.0M$50.0M$75.0M$100.0M2019: $10.6M$10.6M20192020: $14.0M$14.0M2020+32%2021: $21.8M$21.8M2021+56%2022: $39.5M$39.5M2022+81%2023: $57.1M$57.1M2023+45%2024: $78.5M$78.5M2024+37%2025: $95.6M$95.6M2025+22%
Operating income6789105$7.3M in 2025
-$15.0M-$10.0M-$5.0M0$5.0M$10.0M2019: -$2.7M-$2.7M20192020: -$5.0M-$5.0M2020+84%2021: -$7.4M-$7.4M2021+47%2022: -$12.5M-$12.5M2022+70%2023: -$4.2M-$4.2M2023−66%2024: $1.3M$1.3M20242025: $7.3M$7.3M2025+480%
Net income6789105-$37.6M in 2025+1235% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$2.8M-$2.8M20192020: -$4.4M-$4.4M2020+58%2021: -$7.9M-$7.9M2021+78%2022: -$7.9M-$7.9M2022+0%2023: -$4.3M-$4.3M2023−46%2024: -$9.7M-$9.7M2024+125%2025: -$37.6M-$37.6M2025+289%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Net Revenue$103.1M$86.7M
Cost of goods sold$7.5M$8.1M
Gross profit$95.6M$78.5M
Selling, general and administrative$78.7M$71.7M
Research and development$5.1M$2.8M
Depreciation and amortization$2.7M$2.8M
Change in fair value of earnout liabilities-$14.5K
Asset impairment charges$1.8M
Total operating expenses$88.3M$77.3M
Operating income$7.3M$1.3M
Interest expense-$6.8M-$3.1M
Share of losses from equity method investments-$952.5K-$90.0K
Interest income$3.7K$22.0K
Gain on disposal of property and equipment$10.9K
Total other income (expense)-$7.7M-$3.2M
Net loss from continuing operations-$393.1K-$1.9M
Net loss from discontinued operations (including asset impairment charge of $26,472,407 in 2025) (Note 3)-$37.2M-$8.0M
Net loss-$37.6M-$9.9M
Net loss attributable to noncontrolling interest from continuing operations-$5.4K-$3.2K
Net loss attributable to noncontrolling interest from discontinued operations-$244.1K
Less: Total net loss attributable to noncontrolling interest-$5.4K-$247.4K
Net loss attributable to Sanara MedTech shareholders-$37.6M-$9.7M
Continuing operations, basic-$0-$0
Continuing operations, diluted-$0-$0
Discontinued operations, basic-$4-$1
Discontinued operations, diluted-$4-$1
Net loss per share of common stock, basic-$4.36-$1.14
Net loss per share of common stock, diluted-$4.36-$1.14
Weighted average number of common shares outstanding, basic8.6M shares8.5M shares
Weighted average number of common shares outstanding, diluted8.6M shares8.5M shares
Asset impairment charge being for discontinued operations$26.5M

Compare Sanara MedTech Inc. with another company

Corporate structure

Sanara MedTech Inc. sits at the top of its group. 12 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Sanara MedTech Inc.

  • TALL PINES CAPITAL, LLC Filed SCHEDULE 13G/A on Sanara MedTech Inc., latest Jul 31, 2026 (2 filings since Oct 8, 2024)
  • BAIRD TRUST Co Filed SCHEDULE 13G/A on Sanara MedTech Inc., latest Apr 14, 2026 (2 filings since Feb 6, 2026)
  • Sanara MedTech Inc. Fort Worth, Texas
    • CarePICS, LLC Subsidiary · Delaware, United States
    • Cellerate, LLC Subsidiary · Texas, United States
    • Pixalere Healthcare USA, LLC Subsidiary · Delaware, United States
    • Precision Healing, LLC Subsidiary · Delaware, United States
    • Rochal Technologies, LLC Subsidiary · Texas, United States
    • Sanara CMP, LLC Subsidiary · Texas, United States
    • Sanara Collagen Peptides, LLC Subsidiary · Delaware, United States
    • Sanara MedTech Applied Technologies, LLC Subsidiary · Texas, United States
    • Scendia Biologics, LLC Subsidiary · Delaware, United States
    • Tissue Health Plus, LLC Subsidiary · Delaware, United States
    • Wound Care Innovations, LLCTT Subsidiary · Nevada, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Sanara MedTech Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.1M5 Dec 31, 2025$1.0M5 Dec 31, 2024+8.5%
Accumulated depreciation$672.9K5 Dec 31, 2025$608.6K5 Dec 31, 2024+10.6%
Property and equipment, net$457.0K5 Dec 31, 2025$432.3K5 Dec 31, 2024+5.7%
Operating-lease assets (leased space)$2.1M5 Dec 31, 2025$1.4M5 Dec 31, 2024+43.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$16.6M5 Dec 31, 2025$15.9M5 Dec 31, 2024+4.4%
Stakes in other companies (equity method)$13.6M5 Dec 31, 2025$5.2M5 Dec 31, 2024+161.4%
Long-term investments$14.6M5 Dec 31, 2025$6.2M5 Dec 31, 2024+135.4%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$3.6M5 Dec 31, 2025$3.6M5 Dec 31, 20240%
Intangible assets, net (excluding goodwill)$18.6M5 Dec 31, 2025$23.5M5 Dec 31, 2024−20.6%
Finite-lived intangibles, net$18.6M5 Dec 31, 2025$41.0M10 Dec 31, 2024−54.5%

Inventory

ItemLatestA year beforeChange
Inventory, total$3.9M5 Dec 31, 2025$2.8M5 Dec 31, 2024+43.4%

Properties, in its own words

We do not own any buildings or other real property. As of December 31, 2025, our leased office space in Fort Worth, Texas consisted of approximately 15,291 square feet of rentable space located in Summit Office Park, a twin-building, mid-rise, 242,000 square foot office park located on the perimeter of the Fort Worth central business district. In March 2025, we amended our primary office lease to obtain additional space, as well as to extend the lease term. The lease had a remaining lease term of 63 months as of December 31, 2025.

As of December 31, 2025, our leased office space in San Antonio, Texas consisted of approximately 7,289 square feet of rentable space located in a 14,500 square foot office park in an industrial district in San Antonio, Texas. In August 2025, we renewed the lease for an additional three-year term. This lease had a remaining lease term of 32 months as of December 31, 2025.

The rest of Item 2

We periodically enter into operating lease contracts for office space and equipment. Arrangements are evaluated at inception to determine whether such arrangements constitute a lease. In accordance with the transition guidance of Accounting Standards Codification Topic No. 842, such arrangements are included in our balance sheet.

See Note 8 to the consolidated financial statements for additional information on our operating leases.

Item 2 of the 10-K filed Mar 24, 2026.4

Leadership

Who has led Sanara MedTech Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. J. Michael Carmena2018
  2. Zachary B. Fleming2022–2024
  3. Ronald T. Nixon2024–2025
  4. Suresh Muppalla V.2025
  5. Seth D. Yon2025–now

President

  1. Deborah Jenkins Hutchinson2010–2017
  2. Shawn M. Bowman2020–2022
  3. Zachary B. Fleming2020–2021
  4. Christopher A. Morrison2021–2022
  5. Rebecca E. McMahon2021–2023

Chief financial officer

  1. Darren Stine2014
  2. J. Michael Carmena2018
  3. Elizabeth B. Taylor2025–now

Chief operating officer

  1. Jacob A. Waldrop2024–now
2010201520202025
Board members and other officers (23)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Chief Financial OfficerMichael D. McNeil named Jun 2, 2022 to Aug 11, 202348

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • CarePICS, LLC Delaware3
  • Cellerate, LLC Texas3
  • Pixalere Healthcare USA, LLC Delaware3
  • Precision Healing, LLC Delaware3
  • Rochal Technologies, LLC Texas3
  • Sanara CMP, LLC Texas3
  • Sanara Collagen Peptides, LLC Delaware3
  • Sanara MedTech Applied Technologies, LLC Texas3
  • Scendia Biologics, LLC Delaware3
  • Tissue Health Plus, LLC Delaware3
  • Wound Care Innovations, LLCTT Nevada3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • WOUND MANAGEMENT TECHNOLOGIES, INC.Aug 12, 2008 to Apr 3, 20192
  • MB SOFTWARE CORPOct 28, 1996 to Jun 10, 20082
  • INAV TRAVEL CORPORATIONJul 22, 1996 to May 3, 19962

Timeline

  1. Oct 1, 20268-K Shareholder vote; Other events49
  2. Aug 11, 20268-K Entered a material agreement; Regulation FD disclosure50
  3. Aug 11, 20268-K Results of operations51
  4. Jul 29, 20268-K Entered a material agreement; Regulation FD disclosure52
  5. Jun 9, 20268-K Shareholder vote53
  6. Jun 4, 20268-K Ended a material agreement54
  7. May 11, 20268-K Results of operations55
  8. Mar 24, 20268-K Results of operations56
  9. Mar 2, 20268-K Regulation FD disclosure57
  10. Jan 23, 20268-K Results of operations58
  11. Nov 26, 20258-K Regulation FD disclosure59
  12. Nov 12, 20258-K Results of operations60
  13. Sep 16, 2025New chief executive Seth D. Yon becomes CEO14
  14. Apr 15, 2025New chief executive Suresh Muppalla V. becomes CEO13
  15. Jun 14, 2024New chief executive Ronald T. Nixon becomes CEO15
  16. Jan 4, 2022New chief executive Zachary B. Fleming becomes CEO16
  17. Feb 26, 2018New chief executive J. Michael Carmena becomes CEO17

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.09 a share, on Nov 12, 2025.61

When it reported results

  1. Aug 11, 2026Reported quarterly or annual results51
  2. May 11, 2026Reported quarterly or annual results55
  3. Mar 24, 2026Reported quarterly or annual results56
  4. Jan 23, 2026Reported quarterly or annual results58
  5. Nov 12, 2025Reported quarterly or annual results60
  6. Nov 12, 2025Reported quarterly or annual results62
  7. Aug 13, 2025Reported quarterly or annual results63
  8. May 14, 2025Reported quarterly or annual results64

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

261 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 71 major events, 126 insider forms, 4 large holders, 3 private raises, 37 other. The latest 20:

  1. Oct 1, 20268-K CURRENT REPORT EDGAR
  2. Sep 16, 20264 EDGAR
  3. Sep 4, 2026DEFM14A PROXY STATEMENT EDGAR
  4. Aug 20, 2026425 EDGAR
  5. Aug 11, 202610-Q EDGAR
  6. Aug 11, 2026425 EDGAR
  7. Aug 11, 20268-K EDGAR
  8. Aug 11, 2026425 EDGAR
  9. Aug 11, 20268-K/A EDGAR
  10. Jul 31, 2026SCHEDULE 13G/A EDGAR
  11. Jul 30, 2026425 EDGAR
  12. Jul 30, 2026425 EDGAR
  13. Jul 30, 2026425 EDGAR
  14. Jul 30, 2026425 EDGAR
  15. Jul 30, 2026425 EDGAR
  16. Jul 30, 2026425 EDGAR
  17. Jul 30, 2026425 EDGAR
  18. Jul 29, 2026425 8-K EDGAR
  19. Jul 29, 20268-K EDGAR
  20. Jun 9, 20268-K EDGAR

The 261 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

13 open-market trades by officers, directors and large owners since October 2021: 0 buys and 13 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 8, 2022Fleming Zachary B.Chief Executive OfficerSale417$33.00$13.8KForm 4
Nov 4, 2022Fleming Zachary B.Chief Executive OfficerSale563$33.00$18.6KForm 4
Nov 2, 2022Fleming Zachary B.Chief Executive OfficerSale20$33.02$660Form 4
Sep 22, 2022Bowman Shawn M.Sale1,000$27.89$27.9KForm 4
Jul 6, 2022Fleming Zachary B.Chief Executive OfficerSale1,415$22.53$31.9KForm 4
Jul 5, 2022Fleming Zachary B.Chief Executive OfficerSale265$21.45$5.7KForm 4
Jun 29, 2022Fleming Zachary B.Chief Executive OfficerSale294$21.00$6.2KForm 4
Jun 28, 2022Fleming Zachary B.Chief Executive OfficerSale69$21.00$1.4KForm 4
Jun 24, 2022Fleming Zachary B.Chief Executive OfficerSale457$21.00$9.6KForm 4
Jun 17, 2022Bowman Shawn M.Sale1,000$20.02$20.0KForm 4
Oct 26, 2021Fleming Zachary B.Chief Executive OfficerSale1,000$34.04$34.0KForm 4
Oct 20, 2021Bowman Shawn M.Sale1,000$34.19$34.2KForm 4
Oct 5, 2021Fleming Zachary B.Chief Executive OfficerSale1,000$33.10$33.1KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Seth D. Yon51$478.9K$2.3M67
2025Jacob A. Waldrop44$315.0K$867.8K67
2025Suresh V. Muppalla$612.8K$715.8K67
2025Elizabeth B. Taylor50$240.5K$637.1K67
2025Ronald T. Nixon70$248.0K$585.5K67
2024Former ChiefExecutive Officer$116.7K$855.8K67
2024Chief Operating Officer$224.3K$518.2K67

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$34.1M 2020–2023
Money received by yearMoney received by year, 2020–2023: $34.1M in all. Private raises (Form D) $33.5M; PPP loans $583.0K.$0$10M$20M$30M$40M2020 · PPP loans: $583.0K202020212022 · Private raises (Form D): $30.5M20222023 · Private raises (Form D): $3.0M2023
Figures by year
YearPrivate raises (Form D)PPP loansTotal
2023$3.0M–$3.0M
2022$30.5M–$30.5M
2020–$583.0K$583.0K

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Aug 1, 2023Raised $3 million in a private offering of equity48 Form D: 1 investor so far Form D
  2. Jul 1, 2022Raised $16 million in a private offering of equity68 Form D: 1 investor so far Form D
  3. Apr 4, 2022Raised $14.5 million in a private offering of equity69 Form D: 46 investors so far Form D

PPP loans

Paycheck Protection Program loans of $150,000 and up, approved April 2020 to July 2021, from the SBA70. Matched to this company by name and state.

  1. Apr 6, 2020$583.0K PPP loan (first draw) from Cadence Bank70To SANARA MEDTECH INC., Fort Worth TX; $586.2K forgiven Nov 12, 2020

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 74. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.248,827$5.9M0.0%+20,060
Vanguard Capital Management LLC194,897$4.6M0.0%+43,530
Royal Bank Of Canada130,995$3.1M0.0%−394
Stonebridge Wealth Management, LLC129,452$3.1M2.7%−7,447
Aqr Capital Management LLC112,207$2.6M0.0%+72,269
Geode Capital Management, LLC89,179$2.1M0.0%+3,517
Goldman Sachs Group Inc74,198$1.8M0.0%+52,613
Renaissance Technologies LLC67,400$1.6M0.0%+2,720
State Street Corp63,469$1.5M0.0%+780
Squarepoint Ops LLC53,811$1.3M0.0%−19,796
Jane Street Group, LLC50,806$1.2M0.0%+12,222
Marshall Wace, Llp49,457$1.2M0.0%−26,825
Citadel Advisors LLC36,813$868.4K0.0%+5,700
Northern Trust Corp36,441$859.6K0.0%+3,185
Jacobs Levy Equity Management, Inc31,644$746.5K0.0%New
Walleye Capital LLC30,465$718.7K0.0%New
Los Angeles Capital Management LLC26,830$632.9K0.0%New
Vanguard Fiduciary Trust Co26,027$614.0K0.0%+652
Evernest Financial Advisors, LLC25,700$606.3K0.1%New
Morgan Stanley23,628$557.4K0.0%+3,988
Vanguard Portfolio Management LLC23,417$552.4K0.0%+5,287
Hsbc Holdings PLC23,254$549.7K0.0%+5,971
Baird Financial Group, Inc.21,075$497.2K0.0%No change
Qube Research & Technologies Ltd20,400$481.2K0.0%−6,009
D. E. Shaw & Co., Inc.16,370$386.2K0.0%+47

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Sanara MedTech Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSanara MedTech Inc.1
  • CIK0000714256
  • Employer ID (EIN)59-22199944
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company4
  • Incorporated inTexas4
  • Fiscal year endsDecember 311
  • Industry code (SIC)3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address1200 Summit Ave, Suite 414, Fort Worth, TX 761021
  • Phone817-529-23001
  • Shares outstanding9,188,035 as of Aug 7, 202612
  • Public float$147.5M as of Jun 30, 20254
  • AuditorWeaver and Tidwell, L.L.P., Austin, Texas PCAOB ID 410; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceMay 2, 19961
  • Filings732 in all: 4 (180), 8-K (180), 10-Q (56), 10QSB (36), 3 (31), NT 10-Q (23), 10-K (20), 425 (18)1
    All 47 form types

    8-K/A (18), NT 10-K (17), UPLOAD (16), CORRESP (15), 10KSB (11), DEFA14A (10), SC 13D/A (10), DEF 14A (9), 10KSB/A (6), 10-K/A (5), 10QSB/A (5), D (5), DEF 14C (5), PRE 14C (5), 4/A (4), ARS (4), SC 13D (4), 10-Q/A (3), 3/A (3), 424B5 (3), 5 (3), S-8 (3), SC 13G (3), EFFECT (2), PRE 14A (2), S-3 (2), SC 13G/A (2), SCHEDULE 13G/A (2), 8-A12B (1), CERT (1), DEFM14A (1), NTN 10Q (1), PREM14C (1), PRER14A (1), RW (1), S-1 (1), S-1/A (1), S-8 POS (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Mar 24, 2026
    Quarterly report (10-Q) Aug 11, 2026
    Proxy statement (DEF 14A) Apr 17, 2026
    Latest 8-K (8-K) Oct 1, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.001 par valueSMTINasdaq

From the cover page of the 10-K filed Mar 24, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Sanara MedTech Inc. names in Item 1A of its 10-K filed Mar 24, 2026: 2 risks under these headings, as written.4

  • We have had a history of losses, which may continue as we expand our selling efforts.
  • We rely on our research and development partners to design, manufacture and supply certain products we have licensed for marketing. If we or one of our partners fails to perform adequately, fulfill our needs, or comply with regulations, we may be required to incur significant costs or even be subject to enforcement actions. We also may face significant delays in our product introductions and commercialization.

Legal proceedings

From time to time, we may be involved in claims and legal actions that arise in the ordinary course of business. To our knowledge, there are no material pending legal proceedings to which we are a party or of which any of our property is the subject.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70